Please Wait.....
Report
Neuroendocrine Tumor Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 113 Pages I Mordor Intelligence
Neuroendocrine Tumor Treatment Market Analysis
The neuroendocrine tumor treatment market is valued at USD 2.89 billion in 2025 and is forecast to reach USD 4.10 billion by 2030, expanding at a 7.22% CAGR. Rapid capacity additions for medical isotopes, especially Lutetium-177, remove past supply bottlenecks and let hospitals adopt peptide receptor radionuclide therapy (PRRT) as a first-line option. Forthcoming PRRT guidelines, orphan-drug incentives and positive NETTER-2 data continue to widen clinical acceptance. Investors are backing vertically integrated radiopharmaceutical platforms, while liquid biopsy technologies such as NETest sharpen diagnosis and help match patients to targeted agents. Health systems also gain confidence from large deals-ITM's NOVA plant and Curium's Netherlands site-showing that the isotope supply chain can now scale.
Global Neuroendocrine Tumor Treatment Market Trends and Insights
Rising prevalence of NETs
Steadily improving imaging and population aging lift incidence, with Dutch registries counting nearly 1,000 new diagnoses in 2024. Health systems answer by launching specialist NET centers and funding isotope capacity. Clinical teams now detect earlier-stage disease, which broadens the candidate pool for PRRT and targeted agents. Industry surveys estimate 350,000 gastro-enteropancreatic NET patients across the EU and US who need long-term care. Multidisciplinary clinics thus adopt standardized pathways to manage rising caseloads efficiently.
Advances in imaging & diagnostics
NETest liquid biopsy tracks microscopic residual disease more accurately than legacy chromogranin A assays and is being validated across ENETS Centers of Excellence. When paired with high-resolution PET/CT, clinicians gain a near-real-time view of tumor biology and treatment response. This integration supports earlier therapy switches and underpins precision oncology programs now spreading from Europe to the United States. The upgrade shortens diagnostic delays, a long-standing barrier in NET care.
High cost of novel therapeutics
Lutathera infusions require shielded suites, radiation monitoring and specialist staff, pushing total treatment costs well above the drug price. Health technology assessment bodies in Europe now scrutinize cost-per-QALY results before adding agents to formularies. Multidisciplinary hubs are emerging to pool patient volumes, cut duplication and improve cost-effectiveness.
Other drivers and restraints analyzed in the detailed report include:
Expansion of approved targeted & PRRT drugs / Orphan-drug incentives & favorable reimbursement / Isotope (Lu-177/Ga-68) supply bottlenecks /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Somatostatin analogs retained 44.23% share in the neuroendocrine tumor treatment market during 2024, reflecting long-standing use for symptom control and tumor stabilization. PRRT, buoyed by community uptake of [??Lu]Lu-Oxodotreotide, is projected to log a 10.32% CAGR and stands out as the primary growth engine. PRRT protocols gained uniformity through the Italian Association of Nuclear Medicine's new guidelines, encouraging broader European uptake. Parallel advances in manufacturing assure a reliable isotope stream, further sustaining momentum.
Clinical preference now shifts toward combination regimens-PRRT plus somatostatin analogs, or PRRT alongside DNA-repair inhibitors under investigation-thereby widening the addressable population. Chemotherapy preserves its role for poorly differentiated carcinomas, while emerging immunotherapy-chemotherapy trials explore synergy in high-grade disease. Targeted therapy, led by everolimus and cabozantinib, offers individualized options for patients unsuitable for radionuclide therapy, underscoring how the neuroendocrine tumor treatment market keeps diversifying.
The Neuroendocrine Tumor Treatment Market Report is Segmented by Treatment Modality (Somatostatin Analogs (SSAs), Targeted Therapy, Chemotherapy, and More), Indication (Gastrointestinal, Pancreas, Lung and More), End User (Hospitals, Specialty/Oncology Clinics, and More), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).
Geography Analysis
North America led with 39.87% share of the neuroendocrine tumor treatment market size in 2024. Medicare's separate payment for high-cost tracers and the FDA's track record of timely approvals underpin early adoption. Major US cancer centers already integrate PRRT with targeted and checkpoint inhibitors in trial settings, while Canada's universal system reimburses core PRRT indications nationally.
Europe benefits from the EMA's orphan-drug pathway and coordinated payer frameworks that streamline access to rare-disease therapies. Local isotope capacity, notably Curium's Netherlands Lu-177 line, strengthens supply security. Germany, France and the United Kingdom host dense networks of ENETS-accredited centers, ensuring consistent quality across borders. Southern European nations expand capabilities through EU cohesion funds and shared training programs.
Asia-Pacific posts the highest 10.06% CAGR, powered by Japan's swift regulatory clearance of diagnostic agents and China's oncology infrastructure build-out. Australia subsidizes PRRT under the Pharmaceutical Benefits Scheme, while South Korea and India establish partnerships with European isotope firms. Regional manufacturers invest in domestic supply chains to avoid import delays, further accelerating neuroendocrine tumor treatment market penetration.
List of Companies Covered in this Report:
Novartis / Ipsen / Pfizer / Roche / Eli Lilly and Company / Boehringer Ingelheim / Bristol-Myers Squibb / Lantheus / ITM Isotope Technologies Munich / Crinetics Pharmaceuticals / Camurus AB / Tarveda Therapeutics / Hutchmed (Hutchison MediPharma) / Jubilant Radiopharma / Peptidyne Therapeutics / Avion Pharmaceuticals / Exelixis / Merck /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence Of Nets
4.2.2 Advances In Imaging & Diagnostics
4.2.3 Expansion Of Approved Targeted & PRRT Drugs
4.2.4 Orphan-Drug Incentives & Favorable Reimbursement
4.2.5 Adoption Of Multi-Analyte Liquid Biopsy (Netest)
4.2.6 Inclusion Of Nets In Precision-Oncology Trials
4.3 Market Restraints
4.3.1 High Cost Of Novel Therapeutics
4.3.2 Limited Physician Awareness & Diagnostic Delays
4.3.3 Safety Concerns With PRRT/Chemo Regimens
4.3.4 Isotope (Lu-177/Ga-68) Supply Bottlenecks
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technology Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Suppliers
4.7.2 Bargaining Power of Buyers
4.7.3 Threat of New Entrants
4.7.4 Threat of Substitutes
4.7.5 Intensity of Competitive Rivalry
5 Market Size and Growth Forecasts (Value-USD)
5.1 By Treatment Modality
5.1.1 Somatostatin Analogs (SSA)
5.1.2 Peptide Receptor Radionuclide Therapy (PRRT)
5.1.3 Targeted Therapy (TKI/mTOR)
5.1.4 Immunotherapy (ICI)
5.1.5 Chemotherapy
5.1.6 Others (Interferons, Supportive)
5.2 By Indication
5.2.1 Gastrointestinal (Mid-gut)
5.2.2 Pancreas
5.2.3 Lung
5.2.4 Other NET Sites
5.3 By End User
5.3.1 Hospitals
5.3.2 Specialty/Oncology Clinics
5.3.3 Ambulatory Surgery Centers
5.3.4 Academic & Research Institutes
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
6.3.1 Novartis AG
6.3.2 Ipsen SA
6.3.3 Pfizer Inc.
6.3.4 F. Hoffmann-La Roche Ltd.
6.3.5 Eli Lilly and Company
6.3.6 Boehringer Ingelheim GmbH
6.3.7 Bristol Myers Squibb
6.3.8 Lantheus Holdings Inc.
6.3.9 ITM Isotope Technologies Munich
6.3.10 Crinetics Pharmaceuticals
6.3.11 Camurus AB
6.3.12 Tarveda Therapeutics
6.3.13 Hutchmed (Hutchison MediPharma)
6.3.14 Jubilant Radiopharma
6.3.15 Peptidyne Therapeutics
6.3.16 Avion Pharmaceuticals
6.3.17 Exelixis Inc.
6.3.18 Merck & Co.
7 Market Opportunities and Future Outlook
7.1 White-Space and Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security